(Hypertension. 1995;25:1306-1310.)
© 1995 American Heart Association, Inc.
Articles |
Dissociation Between the Antiatherosclerotic Effect of Trandolapril and Suppression of Serum and Aortic Angiotensin-Converting Enzyme Activity in the Watanabe Heritable Hyperlipidemic Rabbit
From the Whitaker Cardiovascular Institute, Boston (Mass) University School of Medicine.
Correspondence to Aram V. Chobanian, MD, Boston University School of Medicine, 80 E Concord St, Boston, MA 02118.
Abstract This study was undertaken to determine whether low doses of the angiotensin-converting enzyme (ACE) inhibitor trandolapril affected atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Trandolapril (10 µg/kg body weight per 48 hours) was begun at 3 months of age and continued for 9 months. The selected dose reduced serum ACE activity but did not influence blood pressure. Both serum and aortic ACE activity were reduced by more than 80% in the trandolapril-treated compared with control WHHL rabbits, similar to the suppression achieved with the 25-fold-higher dose that in our previous studies induced marked inhibition of aortic atherosclerotic lesions in the WHHL rabbit. In contrast to these prior findings, low-dose trandolapril had no effect on aortic surface involvement by atherosclerosis, aortic cholesterol content, or aortic morphology. The data suggest that the antiatherosclerotic action of ACE inhibitors in the WHHL rabbit may not be related directly to arterial enzyme inhibition.
Key Words: angiotensin-converting enzyme inhibitors • atherosclerosis • blood pressure • angiotensin-converting enzyme • rabbits
This article has been cited by other articles:
 |
|
 |
|
  L. Weekers, B. Bouhanick, S. Hadjadj, Y. Gallois, R. Roussel, F. Pean, A. Ankotche, G. Chatellier, F. Alhenc-Gelas, P. J. Lefebvre, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients Diabetes, October 1, 2005; 54(10): 2961 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marre, M. Lievre, G. Chatellier, J. F E Mann, P. Passa, and J. Menard Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ, February 28, 2004; 328(7438): 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Rosenkranz, S. G. Hood, R. L. Woods, G. J. Dusting, and R. H. Ritchie Acute Antihypertrophic Actions of Bradykinin in the Rat Heart: Importance of Cyclic GMP Hypertension, October 1, 2002; 40(4): 498 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Papademetriou, P. Mammillot, R. Redman, A. Notargiacomo, P. Narayan, and R. Lakshman Prevention of atherosclerosis by specific AT1-receptor blockade with candesartan cilexetil Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S77 - S80. [Abstract] [PDF]
|
|
|
|
|
|
A. Kiarash, P. J. Pagano, M. Tayeh, N.-E. Rhaleb, and O. A. Carretero Upregulated Expression of Rat Heart Intercellular Adhesion Molecule-1 in Angiotensin II- but Not Phenylephrine- Induced Hypertension Hypertension, January 1, 2001; 37(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayek, J. Attias, R. Coleman, S. Brodsky, J. Smith, J. L. Breslow, and S. Keidar The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice Cardiovasc Res, December 1, 1999; 44(3): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Makaritsis, H. Gavras, Y. Du, A. V. Chobanian, and P. Brecher {alpha}1-Adrenergic Plus Angiotensin Receptor Blockade Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice Hypertension, December 1, 1998; 32(6): 1044 - 1048. [Abstract] [Full Text] [PDF]
|
|